Table 3.

Comparison of DOPPS data with CMS 2005–2007 facility-level data for facilities in US DOPPS Phase 3

Sample	Facility N	% aged >65	% African American	% with Hgb 10–12 g/dLa	% with URR >65%b	% with catheterc
DOPPS Phase 3	66	44.0	37.3	50.4	91.9	25.8
CMS 2005–2007	66	45.6	34.3	52.9	94.7†	28.2

Hgb= hemoglobin; URR=urea reduction ratio;

^†0.05<p<0.10 for two-sample T test (p≥0.10 if not shown)

Note: Conversion factors for units: hemoglobin in g/dL to g/L, ×10.

CMS 2005–2007 results use CMS data for the year in which the DOPPS facility began participating in US-DOPPS phase 3; DOPPS phase 3 results use DOPPS data collected for a prevalent cross-section of study patients in each US-DOPPS phase 3 facility at the time of initiating DOPPS phase 3 data collection between 2005–2007.

^aHgb - Among Medicare patients with either ESA reimbursement claims (CMS result) or reported ESA prescription (DOPPS result). CMS results are expressed as percentage of patient-months during the year. DOPPS results are based on the mean of two monthly values obtained approximately four months apart.

^bURR - Among Medicare patients only. CMS results are expressed as percentage of patient-months during the year. DOPPS results are based on the mean of two monthly values obtained approximately four months apart.

^cCatheter - CMS results are expressed as percentage of patient-months during the year; DOPPS results are based on vascular access in use at study entry.